Montelukast & Fluticasone Interaction

Montelukast (a leukotriene receptor antagonist) and fluticasone (an inhaled or intranasal corticosteroid) are frequently combined for the management of persistent asthma and/or allergic rhinitis. This combination addresses multiple inflammatory pathways and is generally safe with no clinically significant pharmacokinetic drug-drug interaction. Guidelines support combined use in patients with inadequate control on a single agent.

Montelukast blocks cysteinyl leukotriene receptors (CysLT1), reducing bronchoconstriction, mucus secretion, and eosinophilic inflammation. Fluticasone acts on glucocorticoid receptors in airway epithelial cells, suppressing transcription of pro-inflammatory cytokines (IL-4, IL-5, IL-13). These complementary anti-inflammatory mechanisms target different pathways of the allergic cascade. No pharmacokinetic interaction between the two drugs has been identified.

Clinical studies and guideline recommendations from GINA and NAEPP support adding a leukotriene modifier to an inhaled corticosteroid in patients with mild-to-moderate persistent asthma not adequately controlled on ICS alone. The combination is particularly beneficial in patients with exercise-induced bronchoconstriction or aspirin-exacerbated respiratory disease. Montelukast has a small neuropsychiatric risk (FDA boxed warning) that must be considered in the benefit-risk assessment.

No dose adjustments are typically required when these drugs are combined. Ensure patients are trained on correct inhaler technique for fluticasone. Review montelukast neuropsychiatric risk (mood changes, suicidal ideation) at each visit, per FDA boxed warning. Do not use montelukast as a rescue medication; fluticasone is a controller medication also not for acute relief.

Asthma control assessment at each visit (symptom frequency, rescue inhaler use, exacerbations). Spirometry annually or per guidelines. Monitor for montelukast-associated neuropsychiatric symptoms especially in pediatric patients. Bone density if long-term high-dose fluticasone.

If asthma remains uncontrolled on this combination, step-up to ICS/LABA (e.g., fluticasone/salmeterol) is a preferred guideline option. Omalizumab or dupilumab may be considered for severe allergic asthma.